A total of 1010 women with resected early breast adenocarcinoma, mostly >T1 (68.7%), node-positive (99.6%, N2 in 60%) and ER-positive (77%) were managed with anthracycline and taxane-based chemotherapy (84.2%) and hormonal therapy (78.3%). The gene discussed is ESR1; the disease is breast adenocarcinoma.